More recently, pembrolizumab, based on phase III clinical trial evidence, was approved as first-line therapy R/M HNSCC in combination with platinum-based chemotherapy or as a single agent in patients with PD-L1-positive (CPS ≥ 1) tumor expression [8]. This evidence concerns the gene CD274 and neoplasm.